The demonstrated synergistic efficacy (cell viability, cell proliferation, and neurosphere formation) seen in vitro for combined LSD1 and EGFR inhibition prompted an in vivo evaluation of NCD38 and osimertinib using an orthotopic glioblastoma xenograft mouse model. The gene discussed is EGFR; the disease is glioblastoma.